This 2015 review examines melatonin's potential as a therapeutic agent against gastrointestinal (GI) cancers. It highlights the association between disrupted melatonin rhythms and increased GI cancer risk, as evidenced by epidemiological and experimental studies. Melatonin's anticancer mechanisms include inhibition of cell proliferation, invasion, metastasis, and angiogenesis, as well as promotion
